TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21362575
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil (standard preparation, 50:50 medium‐chain triacylglycerols: soybean oil)
Study: 18640856
Drug: Acetaminophen extended-release
Normalized name: Acetaminophen Extended-Release
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen extended-release (APAP ER) 3900 mg daily
Study: 18640856
Drug: Rofecoxib 12.5
Normalized name: rofecoxib 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 12.5 mg daily
Study: 17538978
Drug: Neoadjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant endocrine therapy with aromatase inhibitors (anastrozole 1 mg/day or exemestane 25 mg/day for 3 months)
Study: 17538978
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (doxorubicin 60 mg/m(2) with paclitaxel 200 mg/m(2) for four 3-week cycles)
Study: 14738791
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (500 mg per day for 5 days)
Study: 15801935
Drug: CHF3381 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF3381 400 mg twice daily
Study: 15801935
Drug: CHF3381 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF3381 100 mg twice daily
Study: 15801935
Drug: CHF3381 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF3381 200 mg twice daily
Study: 10477360
Drug: Carbohydrate‐arginine (CHO/AA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate‐arginine (CHO/AA) supplement (1 g carbohydrate/kg body mass and 0.08 g arginine‐hydrochloride/kg body weight)
Study: 10477360
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) supplement (1 g carbohydrate/kg body weight)
Study: 30837170
Drug: Adjuvanted vaccine
Normalized name: PIKA-adjuvanted vaccine composition
DrugBank: PIKA rabies vaccine (DB17963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted vaccine with 45 μg of LTh(αK)
Study: 30837170
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (22.5 μg of influenza HA antigen alone)
Study: 27586538
Drug: (S)-amlodipine (2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-amlodipine (2.5-5 mg)
Study: 27586538
Drug: Conventional amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional amlodipine (5-10 mg)
Study: 9613231
Drug: Blink-concurrent glissadic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blink-concurrent glissadic saccades
Study: 9283511
Drug: Yohimbine hydrochloride
Normalized name: Yohimbine Hydrochloride
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine hydrochloride (0.4 mg/kg)
Study: 16873702
Drug: rhIGF-I/IGFBP-3 (0.1-0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF-I/IGFBP-3 (0.1-0.8 mg x kg(-1) x day(-1))
Study: 10678614
Drug: High-dose fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fluticasone propionate (1,000 microg x day(‐1))
Study: 10678614
Drug: Low-dose fluticasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fluticasone propionate (100 microg x day(‐1))
Study: 10678614
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after 6 weeks of FP treatment)
Study: 9042816
Drug: beta-carotene (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-carotene (15 mg daily)
Study: 8366412
Drug: Collagen membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen membrane barrier therapy
Study: 3788816
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of dipyridamole
Study: 3788816
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of ASA
Study: 3788816
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of dipyridamole and 25 mg of ASA together
Study: 20207239
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1 g) and Vitamin E (400 IU) supplementation
Study: 27270566
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac
Study: 12450888
Drug: Mixed alpha‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed alpha‐ plus gamma‐tocotrienol supplement
Study: 7439253
Drug: Phenazone (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenazone (1.0 g X 4 for 2 days, then 0.5 g X 4 for the next 2 days)
Study: 24741050
Drug: Alprazolam (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (single oral dose)
Study: 24741050
Drug: Zolpidem (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (single oral dose)
Study: 17618955
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of a mix of inulin and oligofructose (9 subjects)
Study: 15632028
Drug: 2D gated
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2D gated acquisitions (2D-G)
Study: 12358656
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam 0.1 mg.kg‐1
Study: 12212217
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg.kg‐1
Study: 7782427
Drug: D‐tryptophan‐6‐luteinizing hormone‐releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐tryptophan‐6‐luteinizing hormone‐releasing hormone (D‐Trp‐6‐LHRH) depot (Decapeptyl 3.75) for 6 months
Study: 7782427
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive containing 30 micrograms of ethinyl oestradiol plus 150 micrograms of desogestrel for 12 months after GnRHa therapy
Study: 23590327
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care physical therapy
Study: 30565544
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment by primary care physician
Study: 25038977
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 30, 50 or 70 mg/day
Study: 19025526
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (MgSO(4)) infusion
Study: 11477460
Drug: Lycopene (13.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene (13.3 mg)
Study: 10878653
Drug: Carotene mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotene mixture (11.9 mg)
Study: 4020675
Drug: Acetaminophen with
Normalized name: acetaminophen with codeine ORAL ELIXIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen with probenecid (500 mg every 6 hr)
Study: 4020675
Drug: Acetaminophen without
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen without probenecid
Study: 4020675
Drug: Lorazepam with
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam with probenecid (500 mg every 6 hr)
Study: 23455717
Drug: FLOT (biweekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOT (biweekly oxaliplatin plus 5‐fluorouracil continuous infusion and folinic acid plus docetaxel 50 mg/m²)
Study: 23455717
Drug: FLO (biweekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLO (biweekly oxaliplatin plus 5‐fluorouracil continuous infusion and folinic acid)
Study: 23327127
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D (diazepam 0.2 mg/kg)
Study: 23327127
Drug: Group K
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group K (ketamine 5% 30 mg/kg)
Study: 23327127
Drug: Group KD
Normalized name: polyquaternium-7 (76-24 acrylamide-dadmac; 120 kD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group KD (ketamine 5% 10 mg/kg + diazepam 0.2 mg/kg)
Study: 20512109
Drug: No desensitising
Approvals — FDA: no, EMA: no, PMDA: no
Description: No desensitising agent (Group B)
Study: 12641628
Drug: High-dose adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adjuvant I-131 therapy
Study: 10347109
Drug: Midodrine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine and octreotide with 20% human albumin solution (50 to 100 mL daily for 20 days)
Study: 10347109
Drug: Dopamine (2‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (2‐4 micrograms/kg/min) with the same daily amount of albumin
Study: 30408271
Drug: Attention Bias
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention Bias Modification (ABM) therapy
Study: 22329987
Drug: Short-term energy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term energy surfeit treatment (BOOST®)
Study: 15939317
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 mcg
Study: 15939317
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 mcg
Study: 1660825
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of conjugated oestrogen, dosage not specified, duration not specified.
Study: 1660825
Drug: Atropine sulphate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine sulphate, dosage not specified, duration not specified.
Study: 7041323
Drug: Intradermal BCG
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal BCG (0.4 to 0.9 X 10(6) viable units)
Study: 752875
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no BCG immunotherapy)
Study: 15855885
Drug: Daily alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily alcohol intake
Study: 8905028
Drug: Three-weekly chemotherapy
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-weekly chemotherapy (cyclophosphamide 600 mg/m2, carboplatin 300 mg/m2, doxorubicin 50 mg/m2, ifosfamide 5 g/m2)
Study: 8905028
Drug: Four-weekly chemotherapy
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-weekly chemotherapy (cyclophosphamide 600 mg/m2, carboplatin 300 mg/m2, doxorubicin 50 mg/m2, ifosfamide 5 g/m2)
Study: 1756257
Drug: pT2 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: pT2 and G-II carcinomas
Study: 6802691
Drug: Hydrochlorothiazide (HCZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCZ) 50 mg once daily (or 50 mg twice a day for 2 patients)
Study: 6802691
Drug: Hydrochlorothiazide (HCZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCZ) plus Nadolol (40 mg to 240 mg once daily)
Study: 6802691
Drug: Nadolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (40 mg to 240 mg once daily)
Study: 29562396
Drug: Radiofrequency treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency treatment with ultrasound guidance
Study: 24221577
Drug: Irradiated organic
Normalized name: Organix Complete
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiated organic manuka honey (5 ml, four times a day during radiation treatment plus seven days)
Study: 24221577
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (5 ml, four times a day during radiation treatment plus seven days)
Study: 22819187
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of recombinant FSH/GnRH antagonist/recombinant LH/hCG on day 1 (n = 39)
Study: 22819187
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of recombinant FSH/GnRH antagonist/recombinant LH/hCG on day 4 (n = 41)
Study: 11985944
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.35 g/kg of fat-free mass)
Study: 8536758
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and cisplatin (135 mg/m2 or 175 mg/m2 of paclitaxel and 50 mg/m2, 75 mg/m2, or 100 mg/m2 of cisplatin)
Study: 25592751
Drug: 14.5 g
Normalized name: CHLORHEXIDINE GLUCONATE 214.5 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14.5 g spices (black pepper, cinnamon, cloves, garlic, ginger, oregano, paprika, rosemary, and turmeric)
Study: 24151277
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) administration (35 mg once weekly for six months)
Study: 24151277
Drug: Delayed ALN
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed ALN administration (not specified dosage, started four months after surgery)
Study: 11527909
Drug: 0.5% ferric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ferric hyaluronate gel
Study: 9428861
Drug: D-myo-inositol-1,2,6-trisphosphate (1,2,6-IP3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-myo-inositol-1,2,6-trisphosphate (1,2,6-IP3) intravenous bolus dose of 240 mg followed by continuous infusion at 90 mg/h for 24 h
Study: 7641722
Drug: ketamine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine 1.5 mg kg‐1
Study: 2621178
Drug: Acyclovir, 800
Normalized name: Acyclovir, 800 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir, 800 mg tid
Study: 1251139
Drug: Prophylaxis replacement
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis replacement therapy with biweekly administration of 7.5 U/kg of factor IX concentrate
Study: 1251139
Drug: Prophylaxis replacement
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis replacement therapy with weekly administration of 15 U/kg of factor IX concentrate
Study: 1251139
Drug: Prophylaxis replacement
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis replacement therapy (both schemes)
Study: 31448433
Drug: Upadacitinib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib (1 mg to 48 mg)
Study: 31448433
Drug: Tofacitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (5 mg BID)
Study: 31448433
Drug: Upadacitinib (∼12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib (∼12 mg BID)
Study: 31221115
Drug: Preoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiation (Pre-CRT) - two cycles of S-1 and oxaliplatin (SOX), followed by chemoradiation, then surgery and three more cycles of SOX chemotherapy.
Study: 31221115
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (Pre-CT) - three cycles of SOX, followed by surgery and three more cycles of SOX chemotherapy.
Study: 28646390
Drug: Laser +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser + topical drug (calcipotriol ointment)
Study: 28646390
Drug: Drug alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug alone (calcipotriol ointment)
Study: 21640878
Drug: Oral B
Normalized name: bran ORAL BOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B mouthwash
Study: 21640878
Drug: All mouthwashes
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All mouthwashes (Chlorhexidine, Oral B, Persica)
Study: 16769002
Drug: 3-S saphenectomy
Normalized name: (S)-3-Isobutyl GABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-S saphenectomy technique (sclerosis injection at the sapheno-femoral junction with microfoam through a catheter, with saphenectomy and distal phlebectomies)
Study: 12685950
Drug: Hyoscinbutylbromide in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscinbutylbromide in infusion
Study: 1753422
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of norfloxacin (chemoprophylaxis)
Study: 1753422
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (without any antimicrobials except when overt UTI occurred)
Study: 6760378
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of azathioprine
Study: 6760378
Drug: 10-15 mg
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-15 mg of prednisone daily
Study: 3882107
Drug: Intravenous BRL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous BRL 26921
Study: 15712339
Drug: Uncertainty management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncertainty management intervention delivered during four weekly telephone sessions with cognitive-behavioral strategies and a self-help manual.
Study: 1685665
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 50 mg remoxipride
Study: 1685665
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 100 mg remoxipride
Study: 1685665
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release capsules (A and B) of 100 mg remoxipride
Study: 31680269
Drug: Routine blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine blood glucose assessment at intervention hospitals; automatic requests for glycated haemoglobin (HbA1c) assessment and notification of diabetes services about patients with blood glucose levels of 14 mmol/L or more.
Study: 19916254
Drug: Ultrasound-guided supraclavicular
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided supraclavicular brachial plexus block with 20 mL of 0.75% ropivacaine
Study: 19916254
Drug: Nerve stimulation
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve stimulation supraclavicular brachus plexus block with 20 mL of 0.75% ropivacaine
Study: 12862299
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (5 mg/kg as a 30 min infusion, followed by 10 mg/kg during 20 hours in GIKM solution)
Study: 12862299
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1000 ml of GIKM alone)
Study: 8523058
Drug: Fluorouracil plus
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil plus levamisole (450 mg/m2 IV daily for 5 days, then weekly for 48 weeks; levamisole 50 mg orally three times daily for 3 days every 2 weeks for 1 year)
Study: 30272088
Drug: 5-year multifactorial
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-year multifactorial intervention consisting of personal health education and contemporary drug treatments for dyslipidemia and hypertension.
Study: 3438580
Drug: Usual medical
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medical treatment
Study: 22622008
Drug: Chemoradiotherapy (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (60 Gy plus concurrent low-dose carboplatin [30 mg/m² per day, 5 days a week for 20 days])
Study: 16134756
Drug: Valsartan (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (20-80 mg per day)
Study: 7808837
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) treatment, 0.5 mg/kg/d for 1 week
Study: 11570643
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) treatment
Study: 30985667
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with PapacarieMBlue
Study: 28398846
Drug: TaxAC (docetaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TaxAC (docetaxel, doxorubicin, and cyclophosphamide or other standard AC and taxane combination regimens)
Study: 24095299
Drug: Etirinotecan pegol
Normalized name: Etirinotecan pegol
DrugBank: Etirinotecan pegol (DB14951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etirinotecan pegol 145 mg/m(2) every 14 days
Study: 24095299
Drug: Etirinotecan pegol
Normalized name: Etirinotecan pegol
DrugBank: Etirinotecan pegol (DB14951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etirinotecan pegol 145 mg/m(2) every 21 days
Study: 20807262
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of caffeine and sulfo-carrabiose
Study: 16913238
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose administration
Study: 26906165
Drug: RTH258 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTH258 4.5 mg
Study: 26906165
Drug: RTH258 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTH258 6.0 mg
Study: 31750396
Drug: ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranibizumab 0.5 mg
Study: 21609286
Drug: Leucine-protein, high-carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucine-protein, high-carbohydrate nutrition (0.1/0.4/1.2/0.2 g·kg(‐1)·h(‐1))
Study: 21609286
Drug: Isocaloric control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric control (0.06/1.6/0.2 g·kg(‐1)·h(‐1))